News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia
Hagop Kantarjian/mdanderson.org
Jan 18, 2024, 11:27

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:

“Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia (R/R ALL). Study now amended to add navitoclax (BCL-xL inhibitor).”

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Read further.
Source: Hagop Kantarjian/X

 

Acute Lymphoblastic Leukemia BCL-XL inhibitor cancer Hagop Kantarjian MD Anderson Cancer Center navitoclax OncoDaily Oncology venetoclax
Special Coverage
Blog
Mar 11, 2025, 01:37
ASCO/AACR Methods in Clinical Cancer Research Workshop
Blog
Mar 11, 2025, 01:20
Recordings of Past SeqSPACE Forums - NCI Division of Cancer Control and Population Sciences
Blog
Mar 10, 2025, 16:42
Miriam Mutebi: What it takes to succeed in medicine and surgery
Blog
Mar 10, 2025, 16:35
Karkinos Healthcare launched the Samvardhini: Towards a Cervical Cancer-Free Future
Blog
Mar 10, 2025, 16:27
Alique Topalian: Presented my posters at the Case Western Reserve University Cancer Disparities conference
Blog
Mar 10, 2025, 16:20
Runcie Chidebe: We need to replicate GF's work in Cervical Cancer to meet the 90/70/90 target
Blog
Mar 10, 2025, 16:13
Layth Mula-Hussain: Submit your abstract for the 4th MDOC Iraq series
Blog
Mar 10, 2025, 16:07
Leave a gift of cancer research in your Will - ICR
Blog
Mar 10, 2025, 16:02
Zero Childhood Cancer will receive a $112.6 million investment from the Australian Government - CCI
Blog
Mar 10, 2025, 15:53
Nelson Dusetti: Honored to be a Keynote Speaker at the 45th EORTC-PAMM Conference
Blog
Mar 10, 2025, 15:36
SPCC's Strategic Leading and Management in the Cancer Care Continuum course
Blog
Mar 10, 2025, 15:17
We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!